Stuart James Connolly

Stuart James Connolly's AcademicInfluence.com Rankings

Medical

#1065

World Rank

#1361

Historical Rank

Cardiology

#64

World Rank

#65

Historical Rank

Epidemiology

#145

World Rank

#157

Historical Rank

medical Degrees

Stuart James Connolly

Philosophy

#3686

World Rank

#5907

Historical Rank

Logic

#1331

World Rank

#2053

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Stuart James Connolly Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stuart James Connolly's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dabigatran versus warfarin in patients with atrial fibrillation. (2009) (8312)
Apixaban in patients with atrial fibrillation. (2011) (1889)
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. (2009) (1867)
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. (2000) (1564)
Cardiac-resynchronization therapy for mild-to-moderate heart failure. (2010) (1559)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (2017) (1499)
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. (2004) (1434)
Rhythm control versus rate control for atrial fibrillation and heart failure. (2008) (1406)
Subclinical atrial fibrillation and the risk of stroke. (2012) (1391)
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. (1991) (1175)
Embolic strokes of undetermined source: the case for a new clinical construct (2014) (1155)
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial (2011) (1141)
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. (2000) (1068)
Effect of dronedarone on cardiovascular events in atrial fibrillation. (2009) (1047)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (2010) (1009)
Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. (1983) (952)
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. (2015) (912)
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT (1997) (898)
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range (2008) (892)
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. (2005) (833)
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014) (776)
Dabigatran versus warfarin in patients with mechanical heart valves. (2013) (760)
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. (2002) (752)
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. (2000) (741)
Newly identified events in the RE-LY trial. (2010) (739)
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. (2015) (738)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. (2016) (675)
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. (2006) (666)
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. (2007) (611)
Amiodarone to Prevent Recurrence of Atrial Fibrillation (2000) (600)
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source (2018) (579)
CYCLICAL VARIATION OF THE HEART RATE IN SLEEP APNOEA SYNDROME Mechanisms, and Usefulness of 24 h Electrocardiography as a Screening Technique (1984) (559)
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. (2010) (545)
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion (2010) (543)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial (2018) (535)
Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events (2014) (523)
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. (2014) (516)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (2019) (514)
Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery: A Meta-Analysis (2002) (502)
Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2013) (487)
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop (2009) (477)
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. (1999) (470)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (2017) (464)
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. (2007) (462)
Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. (2003) (457)
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. (2005) (443)
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (2010) (443)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial (2012) (436)
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. (2014) (417)
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial (2012) (409)
Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation (2018) (377)
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial (2012) (375)
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT (2017) (373)
Dronedarone in high-risk permanent atrial fibrillation. (2011) (368)
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy (2012) (367)
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. (2009) (363)
Quality of life in the Canadian Implantable Defibrillator Study (CIDS). (2002) (362)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016) (359)
New-Onset Atrial Fibrillation: Sex Differences in Presentation, Treatment, and Outcome (2001) (356)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2013) (346)
Historical criteria that distinguish syncope from seizures. (2002) (342)
Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update (2017) (341)
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. (2005) (341)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation (2010) (333)
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators (2009) (330)
Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry (2014) (325)
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. (2011) (313)
Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation (2013) (284)
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin (2013) (282)
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. (2015) (276)
Evidence-based analysis of amiodarone efficacy and safety. (1999) (275)
Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope (2006) (254)
Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (2009) (250)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. (2002) (245)
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (2012) (235)
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) (2008) (235)
Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing: Meta-Analysis of Randomized Trials, Using Individual Patient Data (2006) (233)
Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. (2001) (229)
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. (2018) (229)
Diagnostic criteria for vasovagal syncope based on a quantitative history. (2006) (224)
Rationale and design of the Apixaban for the Reduction of Thrombo‐Embolism in Patients With Device‐Detected Sub‐Clinical Atrial Fibrillation (ARTESiA) trial (2017) (224)
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective (2011) (223)
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding (2013) (223)
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE) (2015) (222)
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study (2013) (222)
Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial (2011) (219)
Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. (1991) (219)
Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study (2013) (216)
Irbesartan in patients with atrial fibrillation. (2011) (215)
Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta‐analysis (2017) (214)
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. (2016) (212)
Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. (1999) (203)
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. (2006) (201)
Device‐Related Infection Among Patients With Pacemakers and Implantable Defibrillators: Incidence, Risk Factors, and Consequences (2010) (201)
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure (2014) (199)
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (2018) (197)
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (2018) (197)
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. (2000) (197)
Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. (1999) (194)
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). (2008) (194)
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. (2015) (190)
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (2016) (190)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Canadian Trial of Physiological Pacing: Effects of Physiological Pacing During Long-Term Follow-Up (2004) (189)
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation (2010) (189)
Atrial pacing periablation for prevention of paroxysmal atrial fibrillation. (1999) (181)
Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. (2003) (179)
Subclinical Atrial Fibrillation in Older Patients (2017) (179)
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). (2012) (178)
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. (2013) (178)
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial (2012) (176)
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. (2010) (173)
2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. (2018) (171)
Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. (2007) (170)
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Trial (2006) (169)
Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis (2005) (169)
The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. (1983) (165)
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. (2021) (162)
Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. (1993) (160)
Post‐Myocardial Infarction Mortality in Patients With Ventricular Premature Depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study (1991) (156)
Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. (2003) (153)
Clinical pharmacology of propafenone. (1983) (153)
Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. (2014) (149)
Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction: Insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT) (2010) (148)
Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT) (2012) (146)
Dual-chamber versus ventricular pacing. Critical appraisal of current data. (1996) (143)
Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial (2012) (138)
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial (2018) (136)
A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation (2009) (136)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial (2019) (133)
Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable (2011) (133)
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. (2010) (131)
Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: Results From the Canadian Implantable Defibrillator Study (CIDS) (2001) (130)
Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. (2012) (128)
Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. (2018) (123)
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) (2013) (123)
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. (2019) (123)
Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. (1999) (121)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors (2013) (120)
Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. (2004) (118)
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. (2011) (118)
Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation (2010) (115)
Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA (3)) study investigators. (2000) (114)
Age of First Faint in Patients with Vasovagal Syncope (2006) (112)
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. (2012) (109)
Asymptomatic or “Silent” Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide (2003) (108)
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) (2018) (106)
Toward Fairness in Data Sharing. (2016) (105)
Patient outcomes using the European label for dabigatran (2013) (105)
Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry (2016) (104)
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review (2017) (104)
Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9–10, 1993 (1993) (104)
Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes (2001) (103)
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. (2010) (102)
Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. (2000) (102)
Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. (2017) (100)
Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators (2009) (100)
Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. (2003) (99)
Are Elderly Patients at Increased Risk of Complications Following Pacemaker Implantation? A Meta‐Analysis of Randomized Trials (2012) (97)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). (2016) (97)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors (2014) (96)
Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review (2011) (92)
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. (2016) (92)
Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial (2012) (91)
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation (2007) (91)
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial (2011) (91)
ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). (2012) (90)
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial (2016) (88)
Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. (2003) (87)
Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. (1989) (86)
Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. (2013) (85)
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score (2017) (85)
Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. (2005) (84)
Rationale and Design of ATHENA: A Placebo‐Controlled, Double‐Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter (2007) (84)
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. (2019) (83)
Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. (1983) (82)
Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. (1992) (81)
Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. (2001) (81)
Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update (2012) (81)
Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. (2003) (80)
Peri-Procedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin: Results from the RE-LY Randomized Trial (2012) (80)
Myocardial disposition of amiodarone in the dog. (1983) (78)
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. (2013) (78)
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016) (78)
Stroke prevention in nonvalvular atrial fibrillation. (1991) (77)
Stroke Prevention in Atrial Fibrillation II Study (1994) (76)
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry (2018) (76)
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. (2012) (75)
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. (2012) (75)
The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study from the Canadian Registry of Atrial Fibrillation (2004) (75)
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes (2015) (74)
Effects of dabigatran according to age in atrial fibrillation (2017) (74)
Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. (2019) (74)
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. (2015) (74)
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. (2018) (73)
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. (2005) (73)
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? (2013) (72)
Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling (2005) (72)
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease (2019) (69)
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. (2013) (68)
Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin (2009) (68)
Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis (2015) (67)
Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. (2021) (67)
Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study (2001) (66)
Stroke Outcomes in the COMPASS Trial (2019) (65)
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. (2019) (65)
Dronedarone in patients with congestive heart failure: insights from ATHENA (2010) (63)
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). (2011) (62)
Interaction Between Digoxin and Dronedarone in the PALLAS Trial (2014) (61)
Re-Ly study of stroke prevention in atrial fibrillation Dabigatren versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361.10: 1056 (2009) (61)
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. (2019) (61)
Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. (1987) (59)
The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. (2000) (59)
Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review (2018) (58)
Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). (2013) (57)
Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design (2009) (56)
Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke: Embolic Stroke of Undetermined Source Global Registry (2016) (56)
Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death: The ALPHEE Study (2011) (55)
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). (2015) (55)
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. (2019) (54)
Meta-analysis of antiarrhythmic drug trials. (1999) (54)
Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices (2013) (53)
Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. (2015) (52)
Predictors of early and late stroke following cardiac surgery (2014) (51)
Prognostic differences between atrial fibrillation and atrial flutter. (2004) (51)
Additional events in the RE-LY trial. (2014) (51)
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. (2016) (50)
Causes of Death and Influencing Factors in Patients With Atrial FibrillationClinical Perspective (2013) (50)
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease (2020) (49)
Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. (2012) (49)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective (2016) (48)
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. (2018) (48)
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy (2014) (48)
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation (2017) (47)
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study (2022) (47)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (46)
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. (2018) (46)
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. (2020) (46)
High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme (2016) (45)
Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke (2015) (45)
ANNEXATM-R: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, DEMONSTRATING REVERSAL OF RIVAROXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS (2015) (45)
The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. (2005) (44)
Canadian Registry of ICD Implant Testing Procedures (CREDIT): Current Practice, Risks, and Costs of Intraoperative Defibrillation Testing (2010) (44)
Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. (2012) (43)
Role of oral anticoagulation in management of atrial fibrillation (2004) (43)
Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) (2006) (43)
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. (2014) (43)
Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure (2015) (42)
Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial (2017) (41)
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study (2011) (40)
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. (2010) (40)
Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. (2022) (39)
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. (2003) (39)
A Randomized‐Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial (2012) (39)
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. (2006) (38)
Atrial fibrillation is associated with increased mortality: causation or association? (2013) (38)
Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). (2010) (38)
Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. (2002) (38)
INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION (2011) (37)
455: REVERSAL OF FACTOR XA INHIBITORS-INDUCED ANTICOAGULATION IN HEALTHY SUBJECTS BY ANDEXANET ALFA (2014) (36)
Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. (1993) (36)
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. (2019) (35)
Pharmacodynamics of Intravenous Amiodarone in the Dog (1984) (35)
Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Lne Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): a Randomized Trial (2012) (34)
Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial (2018) (34)
2004 Canadian Cardiovascular Society Consensus Conference: Atrial Fibrillation. (2005) (33)
Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (2012) (33)
Relevance of Electrical Remodeling in Human Atrial Fibrillation: Results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial Mechanisms of Atrial Fibrillation Study (2012) (33)
Combined Antiplatelet Therapy in Atrial Fibrillation: (2003) (33)
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial (2013) (33)
Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials (2007) (33)
Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. (2006) (32)
Atrial fibrillation detected initially during acute medical illness: A systematic review (2018) (32)
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. (2020) (32)
Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta‐analysis (2016) (32)
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry (2019) (32)
Clinical Pharmacokinetics of N-acetylprocainamide (1982) (32)
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation (2013) (31)
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. (2020) (31)
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial (2020) (31)
The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: a randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. (2012) (31)
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. (2014) (31)
Use and misuse of surrogate outcomes in arrhythmia trials. (2006) (31)
The CHA 2 DS 2-VASc score identifies those patients with atrial fibrillation and a CHADS 2 score of 1 who are unlikely to benefit from oral anticoagulant therapy (2012) (31)
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) (2020) (29)
Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. (2003) (29)
The management of patients with carotid sinus syndrome: is pacing the answer? (2004) (29)
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. (2020) (29)
Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. (2014) (28)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) (2014) (28)
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial (2017) (28)
Metoprolol prophylaxis against postoperative atrial fibrillation increases length of hospital stay in patients not on pre-operative β blockers: the β blocker length of stay (BLOS) trial (2004) (28)
Clinical trials of pacing mode selection. (2000) (27)
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation (2008) (27)
Comparison of mortality from acute myocardial infarction between 1979 and 1992 in a geographically defined stable population. (1996) (27)
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. (2012) (26)
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy (2012) (26)
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. (2022) (26)
Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). (2018) (26)
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. (2016) (26)
Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy? (1999) (26)
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. (2019) (26)
The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review (2017) (26)
Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS2 and CHA2DS2-VASc Scores in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study (2013) (26)
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial (2020) (26)
Atrial overdrive pacing in sleep apnoea: a meta-analysis. (2009) (25)
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. (2021) (25)
EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY (2010) (25)
Anticoagulation for patients with atrial fibrillation and risk factors for stroke (2000) (25)
Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). (2003) (25)
Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. (1984) (24)
Second Vasovagal Pacemaker Study (VPS II): rationale, design, results, and implications for practice and future clinical trials. (2003) (24)
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. (2019) (24)
Effect of Metoprolol on Quality of Life in the Prevention of Syncope Trial (2009) (24)
Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis. (2019) (24)
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source (2020) (23)
Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial (2016) (23)
Efficacy and Safety of Dabigatran vs . Warfarin in Patients With Atrial Fibrillation – Sub-Analysis in Japanese Population in RELY Trial – (2011) (23)
Circadian variation of paroxysmal atrial fibrillation (2001) (23)
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. (2013) (22)
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. (2008) (22)
Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. (2021) (22)
Cost-effectiveness of physiologic pacing: results of the Canadian Health Economic Assessment of Physiologic Pacing. (2005) (22)
COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL (2014) (22)
Knowledge to action: Rationale and design of the Patient‐Centered Care Transitions in Heart Failure (PACT‐HF) stepped wedge cluster randomized trial (2017) (22)
Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. (2003) (22)
Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation (2014) (22)
Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle-aged individuals. (2020) (22)
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes (2008) (21)
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis (2018) (21)
Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. (2019) (21)
reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (prt064445), an antidote for direct and indirect fxa inhibitors—a phase 2 randomized, double-blind, placebo-controlled trial : Coa01 (2014) (21)
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. (2020) (21)
Concentration response relationships of amiodarone and desethylamiodarone. (1988) (21)
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. (2016) (20)
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. (1991) (20)
Clinical review of radiofrequency catheter ablation for cardiac arrhythmias. (2003) (20)
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. (2021) (20)
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial (2022) (20)
Definition of predicted effective antiarrhythmic drug therapy for ventricular tachyarrhythmias by the electrophysiologic study approach: randomized comparison of patient response criteria. (1997) (20)
Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study (2004) (19)
Atrial fibrillation occurring transiently with stress (2018) (19)
Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration (2022) (19)
Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials (2016) (19)
The diurnal variability of ventricular premature depolarizations: influence of heart rate, sleep, and wakefulness. (1989) (19)
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. (2018) (19)
Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa (2016) (19)
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population : The GENETIC-AF Trial (2019) (18)
Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. (2003) (18)
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran (2018) (18)
North American Vasovagal Pacemaker Study: Study Design and Organization (1997) (18)
Management and Outcomes of Major Bleeding On Dabigatran or Warfarin (2012) (18)
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. (2016) (18)
Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and Recurrent Arrhythmias (2008) (17)
Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). (2017) (17)
Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. (2010) (17)
Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial (2017) (17)
Prognostic impact of demographic factors and clinical features on the mode of death in high‐risk patients after myocardial infarction – A combined analysis from multicenter trials (2005) (17)
Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies (2011) (16)
Worsening of Symptoms Before Presentation with Vasovagal Syncope (2007) (16)
The use of dabigatran according to body mass index : the RE-LY experience (2014) (16)
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score. (2015) (16)
Life and death after ICD implantation. (2008) (16)
Embolic strokes of undetermined source: support for a new clinical construct–Authors' reply (2014) (16)
Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial (2014) (15)
DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS (2010) (15)
Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. (2016) (15)
Asians and Non-Asians With Atrial Fibrillation Dabigatran Versus Warfarin : Effects on Ischemic and Hemorrhagic Strokes and Bleeding (2013) (15)
Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. (2011) (15)
Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation (2021) (15)
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. (2003) (15)
“An AVID Dissent”: Commentary (1994) (15)
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation (2020) (15)
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study (2017) (15)
Benzodiazepine administration during adult cardiac surgery: a survey of current practice among Canadian anesthesiologists working in academic centres (2018) (15)
Comparison of one-, six- and 24-hour ambulatory electrocardiographic monitoring for ventricular arrhythmia as a predictor of mortality in survivors of acute myocardial infarction. CAMIAT Pilot Study Group. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. (1992) (14)
Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol (2016) (14)
Assessment of Resynchronization Therapy on Functional Status and Quality of Life in Patients Requiring an Implantable Defibrillator (2009) (14)
Atrial fibrillation: guiding lessons from epidemiology. (2004) (14)
Warfarin in heart failure. (2012) (14)
Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study (2014) (14)
Potential demographic and baselines variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator--a prognostic indicator. (2008) (14)
Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy (2014) (14)
Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice (2005) (14)
Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2014) (14)
Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. (2018) (14)
The role of randomized cluster crossover trials for comparative effectiveness testing in anesthesia: design of the Benzodiazepine-Free Cardiac Anesthesia for Reduction in Postoperative Delirium (B-Free) trial (2018) (14)
Should patients with cardiovascular disease take fish oil? (2008) (13)
Diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. (2009) (13)
Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). (2014) (13)
Age and mental health predict early device-specific quality of life in patients receiving prophylactic implantable defibrillators. (2012) (13)
Thromboembolic events occur despite sinus rhythm maintenance in patients treated for atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience. (2004) (12)
Abstract 4097: Rhythm- and Rate-Controlling Effects of Dronedarone in Patients with Atrial Fibrillation: Insights From the ATHENA Trial (2008) (12)
Prospective study of tricuspid valve regurgitation associated with permanent leads in patients undergoing cardiac rhythm device implantation: Background, rationale, and design (2015) (12)
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. (2016) (12)
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial (2019) (12)
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. (2020) (12)
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices (2014) (12)
Dabigatran etexilate and reduction in serum apolipoprotein B (2015) (12)
Anticoagulant-Related Bleeding and Mortality. (2016) (12)
Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. (2020) (12)
Design and Use of a Quantitative Scale for Measuring Presyncope (2009) (12)
Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow‐up cohort study (2018) (12)
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. (2020) (12)
Circadian variation of paroxysmal atrial fibrillation. PA3 Investigators. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. (2001) (12)
Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. (2000) (11)
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. (2013) (11)
The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C‐CUSP ED) (2019) (11)
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial (2018) (11)
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials (2020) (11)
The Relationship Between Atrial High-Rate Episodes and Stroke: The Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT) Trial (2010) (11)
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation (2021) (11)
Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. (2019) (11)
Beta-blockers in syncope: the jury is still out. (2001) (11)
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? (2010) (11)
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis (2022) (10)
Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far? (2014) (10)
The Second Vasovagal Pacemaker Study (VPSII) (2003) (10)
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. (2015) (10)
A genotype‐directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC‐AF trial (2017) (10)
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. (2019) (10)
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. (2014) (10)
Prevention of Vascular Events in Patients with Atrial Fibrillation: (2003) (9)
Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction (1992) (9)
Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter (2012) (9)
Andexanet Alfa for Factor Xa Inhibitor Reversal. (2016) (9)
Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial (2019) (9)
Restricted versus liberal intraoperative benzodiazepine use in cardiac anaesthesia for reducing delirium (B-Free Pilot): a pilot, multicentre, randomised, cluster crossover trial. (2020) (9)
Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy (2010) (9)
Registry on the evaluation of syncope assessment strategy in the emergency room (RESASTER study) (2005) (9)
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage (2021) (9)
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE‐LY trial analysis (2018) (9)
Amiodarone Interaction With (cid:98) -Blockers Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases amiodarone in patients after myocardial infarction with sim-Received (1999) (9)
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): rationale, design and specific aims. (2003) (9)
Management of dyspepsia symptoms on dabigatran during RELY-ABLE : long-term follow up study after RE-LY (2013) (9)
Apical versus Non‐Apical Lead: Is ICD Lead Position Important for Successful Defibrillation? (2016) (9)
Atrial fibrillation in 2010: Advances in treatment and management (2011) (9)
Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. (2017) (9)
The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: a substudy of the Canadian Trial of Physiological Pacing (CTOPP). (2007) (9)
Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial (2012) (8)
Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. (2006) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation (2013) (8)
Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard. (2014) (8)
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care (2021) (8)
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial (2021) (8)
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients (2021) (8)
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban (2022) (8)
Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons (2018) (8)
Permanent pacemaker therapy for neurally mediated syncope. (2012) (8)
Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope. Second vasovagal pacemaker study (VPS II): a randomized trial ☆ (2003) (8)
Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. (2003) (8)
Atrial deformation: the key to maintenance of sinus rhythm in patients with atrial fibrillation? (2008) (7)
Efficacy and safety of dabigatran versus warfarin from the RE-LY trial (2018) (7)
Device-Detected Atrial Fibrillation Before and After Hospitalization for Non-cardiac Surgery or Medical Illness: Insights from ASSERT. (2020) (7)
Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation (2002) (7)
Abstract 15537: Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial (2012) (7)
Abstract 9174: Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry (2011) (7)
Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding (2022) (7)
Abstract 20413: Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis (2014) (7)
The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. (2012) (7)
Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis (2013) (7)
30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING (2020) (7)
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline (2020) (7)
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study (2020) (6)
P4602Similar clinical outcomes of asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF (2017) (6)
Amiodarone for Patients With Ventricular Premature Depolarizations After Myocardial Infarction Is It Safe to Stop Treatment at One Year? (1993) (6)
Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic Agents (2014) (6)
Prophylactic antiarrhythmic therapy for the prevention of sudden death in high-risk patients : drugs and devices (1999) (6)
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. (2012) (6)
Effectiveness of single‐ vs dual‐coil implantable defibrillator leads: An observational analysis from the SIMPLE study (2019) (6)
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. (2022) (6)
Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial. (2019) (6)
Canadian amiodarone myocardial infarction arrhythmia trial (CAMAT) : rationale and protocol (1993) (5)
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation (2022) (5)
GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population. (2019) (5)
176 Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers. (2016) (5)
Prevention of Infections in Cardiac Surgery study (PICS): study protocol for a pragmatic cluster-randomized factorial crossover pilot trial (2018) (5)
Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials (2020) (5)
QUALITY OF LIFE COMPARISON BETWEEN THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR AND AMIODARONE (1999) (5)
DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS (2011) (5)
Canadian Implantable Defibrillator Study (CIDS): Perspective of the Principal Investigators (1998) (5)
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). (2021) (5)
Abstract 12862: Predictors of Hospitalization and Effects of Dabigatran and Warfarin on Hospitalization Rates: An Analysis From The Re-ly Trial (2015) (5)
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. (2019) (5)
Sunday, 26 August 2012 (2012) (5)
Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation : Analysis in Asian Population in RE-LY Trial (2012) (5)
DABIGATRAN ETEXILATE VERSUS WARFARIN IN PATIENTS WITH DIFFERENT TYPES OF ATRIAL FIBRILLATION: A RE-LY® SUBGROUP ANALYSIS (2011) (5)
Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events". (2015) (4)
High-Sensitivity Estimate of the Incidence of New-Onset Atrial Fibrillation in Critically Ill Patients (2020) (4)
Abstract 14808: Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy (2012) (4)
PREDICTORS OF DEATH AND STROKE IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION: Results FROM THE CANADIAN REGISTRY OF ATRIAL FIBRILLATION (2014) (4)
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". (2014) (4)
Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation (2008) (4)
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES (2020) (4)
Derivation and validation of a two‐variable index to predict 30‐day outcomes following heart failure hospitalization (2021) (4)
Statin use reduces incidence of adverse events in patients with atrial fibrillation: analysis in ACTIVE-W & A and AVERROES studies (2014) (4)
Abstract 12492: Cystatin C is Prognostic for Stroke, Death and Bleeding in Atrial Fibrillation - A RELY Substudy (2011) (4)
Reply: regarding the effect of dabigatran plasma concentrations. (2014) (4)
Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial. (2013) (4)
Right ventricular tachycardia: common presentation versus common disease. (2013) (4)
Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT (2019) (4)
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. (2021) (4)
Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial (2018) (4)
on behalf of the RE-LY Atrial Fibrillation Registry Investigators (2014) (4)
NAVIGATE ESUS: Phase-III RCT assessing prevention of stroke and systemic embolism in patients with embolic stroke of undetermined source (2015) (4)
Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation. (2017) (4)
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. (2021) (4)
Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation (2021) (4)
Contralateral Pneumothorax in Left Sided CRT Device Implantation (2011) (3)
Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy (2010) (3)
LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry (2021) (3)
Andexanet Alfa for Bleeding with Factor Xa Inhibitors. Reply. (2019) (3)
Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds (2019) (3)
Refined risk stratification by heart rate turbulence in patients with reduced left ventricular function early after myocardial infarction: Results of the DINAMIT Holter substudy (2005) (3)
Prevention and Treatment of Life‐Threatening Ventricular Arrhythmia and Sudden Death (2007) (3)
Appropriate Use of the Implantable Cardioverter Defibrillator: A Canadian Perspective (1999) (3)
Monday, 27 August 2012 (2012) (3)
A rare cause of implantable cardioverter-defibrillator failure: short-circuiting via an unused pace/sense lead. (2010) (3)
Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia. (2000) (3)
818b – A Randomized Trial of Proton Pump Inhibitors Versus Placebo to Prevent Upper Gastrointestinal Bleeding in Patients Receiving Rivaroxaban Or Aspirin (2019) (3)
33: PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF ANDEXANET ALFA DOSE IN ACUTE MAJOR BLEEDING (2018) (3)
579 The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis (2019) (3)
Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial (2015) (3)
Society Guidelines 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation (2014) (3)
ATRIAL FIBRILLATION OCCURRING TRANSIENTLY WITH STRESS DURING MEDICAL ILLNESS: A SYSTEMATIC REVIEW (2016) (3)
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect (2017) (3)
Introduction (2003) (3)
314 Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers by Andexanet Alfa (2017) (3)
5770A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials (2017) (2)
THE CHA2DS2-VASC SCORE IDENTIFIES AF PATIENTS WITH A CHADS2 SCORE OF 0 OR 1 TREATED WITH ANTIPLATELET THERAPY WHO ARE UNLIKELY TO BENEFIT FROM ORAL ANTICOAGULANT THERAPY (2012) (2)
Physiologic pacing: where pacing mode selection reflects the indication (2004) (2)
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial (2021) (2)
Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD registry (2013) (2)
Periprocedural and Long‐Term Anticoagulation (2011) (2)
Implantable cardioverter defibrillators—for whom? (1998) (2)
Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT) (2021) (2)
Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". (2012) (2)
Mo1999 How Often Does Major Gastrointestinal Bleeding in Patients Receiving Warfarin or Dabigatran Uncover Cancer? The U.S. Experience From the RELY Trial (2015) (2)
The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: Role of amiodarone** (1998) (2)
RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years (2013) (2)
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial (2014) (2)
202: ANDEXANET ALFA REVERSES ANTICOAGULATION INDUCED BY BETRIXABAN IN HEALTHY VOLUNTEERS (2018) (2)
Real-world experience with atrial fibrillation ablation: cause for concern. (2014) (2)
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials (1997) (2)
Abstract 12041: The Risk of Peri-Operative Bleeding with Warfarin Compared to Two Doses of Dabigatran: Results From the RE-LY Trial (2011) (2)
Prospective long-term follow-up of silicone-polyurethane–insulated implantable cardioverter-defibrillator leads (2021) (2)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. (2022) (2)
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease (2021) (2)
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION (2016) (2)
Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. (2016) (2)
Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation (2020) (2)
EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS (2013) (2)
Abstract 11087: Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial (2013) (2)
When and how should we cluster and cross over: methodological and ethical issues (letter 1) (2018) (2)
Therapies for the prevention of stroke and other vascular events in atrial fibrillation and atrial flutter. (2005) (2)
REDUCTION IN UNNECESSARY VENTRICULAR PACING FAILS TO AFFECT HARD CLINICAL OUTCOMES: A META-ANALYSIS (2015) (2)
Narrow QRS tachycardia with long R-P. (2008) (2)
Bilateral Pneumothorax Post Insertion of Intracardiac Defibrillator, a Rare Condition, Risk Factors and Prevention (2016) (2)
Reply: Anticoagulant-Related Nephropathy. (2015) (2)
Efficacy and Safety of Dabigatran Etexilate vs . Warfarin in Asian RELY Patients According to Baseline Renal Function or CHADS 2 Score (2015) (2)
CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL (2016) (2)
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source (2020) (2)
Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis (2006) (2)
Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial (2017) (2)
Abstract 212: Andexanet Alfa, a Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers (2016) (2)
When and how should we cluster and cross over: methodological and ethical issues (letter 2) (2018) (2)
Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect? (2020) (2)
Small-Volume Tubes to Reduce Transufusion (STRATUS): A Pilot Study (2018) (2)
Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial (2020) (2)
Does left atrial appendage occlusion eliminate the need for warfarin (2009) (2)
Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. (2019) (2)
Antiplatelet Therapy in Patients with Atrial Fibrillation: A Systematic Review and Metaanalysis of Randomized Trials. (2021) (2)
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype (2021) (2)
Abstract 14972: Sub-clinical Atrial Fibrillation in Elderly Primary Care Patients Without Clinical Atrial Fibrillation (2015) (2)
59: ANDEXANET ALFA REVERSES ANTICOAGULATION IN FACTOR XA-ASSOCIATED MAJOR BLEEDING IN ANNEXA-4 STUDY (2019) (2)
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. (2022) (1)
Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction. CAMIAT Pilot Study Group. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. (1992) (1)
Current Attitudes towards Oral Anticoagulant Use to Treat Cardiac Device Patients with Subclinical Atrial Fibrillation : Results from a Four-Nation Physician Survey (2015) (1)
Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients (2011) (1)
Abstract 10162: NT-proBNP is Associated with Stroke, Heart Failure Hospitalizations, and Death in Patients with Atrial Fibrillation Without Oral Anticoagulation Regardless of Heart Rhythm (2021) (1)
STROKE RISK PREDICTION IN PATIENTS WITH ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE: RESULTS FROM THE RE-LY AF REGISTRY (2019) (1)
Abstract TMP117: Characterization of Patients With Embolic Strokes of Uncertain Source in the Navigate-ESUS Trial (2018) (1)
4. Syncope Evaluation & Syncope Unit4.2 Registry on the Evaluation of Syncope Assessment Strategy in the Emergency Room (Resaster Study) (2005) (1)
Indications to Ventricular Tachycardia/Ventricular Fibrillation Ablation and Hybrid Therapy (2009) (1)
Abstract P3: Andexanet Alfa for Acute Bleeding During Treatment With Edoxaban (2021) (1)
Abstract 14433: Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation (2012) (1)
BLEEDING WITH ASPIRIN AND APIXABAN IN PATIENTS UNSUITABLE FOR VITAMIN K ANTAGONIST THERAPY: THE AVERROES STUDY (2012) (1)
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study (2020) (1)
·P-27 Systems of logging exclusions in multicenter clinical trials (1990) (1)
Prevention of vascular events in atrial fibrillation – Authors' reply (2007) (1)
Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools. (2010) (1)
Active-fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights from ASSERT. (2020) (1)
Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial (2013) (1)
Evolution of the implantable cardioverter defibrillator (2002) (1)
Effect of PON 1 Q 192 R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the CURE and ACTIVE Trials (2012) (1)
Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors (2019) (1)
The Spontaneous Variability of Ventricular Arrhythmias (1982) (1)
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". (2013) (1)
818a – Adverse Events Related to Proton Pump Inhibitor Therapy. Results of a Randomized Trial of Pantoprazole Versus Placebo with 53,152 Patient Years of Follow-Up (2019) (1)
Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF (2010) (1)
CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL (2016) (1)
ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (2004) (1)
Abstract P199: Randomized Comparison of the DAWN AC Computer Program and a Simple Manual Nomogram for Quality of Warfarin Dosing (2011) (1)
Syncope Historical Criteria That Distinguish Syncope From Seizures (2016) (1)
Benefits of left atrial appendage occlusion (2006) (1)
Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope (1998) (1)
ANDEXANET ALFA FOR ACUTE BLEEDING DURING TREATMENT WITH ENOXAPARIN (2021) (1)
Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation : insights from the RE-LY trial (2016) (1)
Abstract 2934: Prolonged QRS Duration is Associated with a Marked Increase in Mortality in the AF-CHF Study (2008) (1)
EFFECTS OF DABIGATRAN VERSUS WARFARIN IN RELATION TO LEFT VENTRICULAR HYPERTROPHY IN ATRIAL FIBRILLATION (2016) (1)
P6544All you need is LE: utility of an abbreviated LACE score in predicting 30-day outcomes among patients hospitalized for Heart Failure (HF) (2018) (1)
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". (2014) (1)
Abstract 15542: Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study (2011) (1)
O095 Referral Bias among Electrophysiologists performing atrial fibrillation radio-frequency ablation (AF-RFA) vs electrophysiologists not performing AF-RFA: A randomized evaluation (2014) (1)
115 – Prevention of Stroke in Atrial Fibrillation: Warfarin and New Oral Anticoagulants (2018) (1)
Abstract 18936: Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES (2014) (1)
Anticoagulation therapy for patients with atrial fibrillation. (2000) (1)
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. (2023) (1)
A Case of Long‐RP Tachycardia: What is the Mechanism? (2009) (1)
Semi-Markov Offline Reinforcement Learning for Healthcare (2022) (1)
IMPACT OF DRONEDARONE STARTED RAPIDLY AFTER AMIODARONE DISCONTINUATION (2010) (1)
SURGICAL ABLATION OF ATRIAL FIBRILLATION IN 11 COUNTRIES: THE LAAOS III TRIAL (2016) (1)
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial (2020) (1)
Trials of Physiologic Pacing (2000) (0)
Association of Eligibility for a Sodium-Glucose Co-transporter 2 Inhibitor and Cardiovascular Events in Patients with Atrial Fibrillation. (2022) (0)
Rivaroxaban in Stable Cardiovascular Disease. (2018) (0)
74Subclinical atrial fibrillation before and after acute medical illness or noncardiac surgery: insights from ASSERT (2020) (0)
SAFETY OUTCOMES WITH ANESTHESIOLOGIST DIRECTED SEDATION COMPARED TO NON-ANESTHESIOLOGIST FOR DEFIBRILLATION THRESHOLD TESTING (2017) (0)
Impact of Additional Left Atrial Lines on AF Recurrence in Patients Undergoing Pulmonary Vein Isolation Redo Procedure (2013) (0)
LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROES (2019) (0)
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatmentwithvitaminKantagonists:resultsfrom (2014) (0)
Radiofrequency Catheter Ablation for Cardiac Arrhythmias : A Clinical and Economic Review Technology Report (2002) (0)
CORONARY ARTERY DISEASE The effect of diltiazem and propranolol , alone and in combination , on exercise performance and left ventricular function in patients with stable effort angina : a double-blind , randomized , and placebo-controlled study (0)
Prevention of post-cardiac surgery atrial fibrillation is not associated with decrease in post-operative stroke: meta-analysis (2002) (0)
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban (2015) (0)
P2-118: Will implementing a syncope assessment algorithm at emergency room reduce hospital admissions and health care costs? (2006) (0)
902 Cluster Randomized Controlled Trial to Test the Effect of Computer-Generated Individualized Audit and Feedback to Patients and Physicians on Clinical Outcomes in Atrial Fibrillation Patients Participating in a Large Multi-Center Trial of Dabigatran (2012) (0)
Current Use of Oral Anticoagulants Therapy in Pacemaker Patients With Pacemaker-Detected Atrial Fibrillation: Results From a Four-Nation Physician Survey (2013) (0)
AB28-2: Effect of metoprolol on presyncope burden in the prevention of syncope trial (2006) (0)
Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation an analysis from the SIMPLE study (2018) (0)
Clopidogrel Added to Aspirin Reduces Stroke Risk in Atrial Fibrillation Patients Unsuitable for Vitamin K Antagonist Therapy (2009) (0)
Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure (2015) (0)
199 Efficacy and Safety With Andexanet Alfa in Traumatic Intracranial Hemorrhage: An ANNEXA-4 Substudy (2019) (0)
Correction to: Prevention of Infections in Cardiac Surgery study (PICS): study protocol for a pragmatic cluster-randomized factorial crossover pilot trial (2019) (0)
How Useful is Computed Tomography of the Chest for the Diagnosis of Asymptomatic Right Ventricular Perforation Following Pacemaker Insertion (2016) (0)
Device-detected atrial fibrillation before and after acute cardiac events: insights from ASSERT (2021) (0)
HEART FAILURE OUTCOMES AND PREDICTORS OF SUBCLINICAL ATRIAL FIBRILLATION PROGRESSION (2017) (0)
768 Prevalence and Predictors of Sub-Clinical Atrial Fibrillation in Pacemaker Patients (2012) (0)
The Canadian registry of atrial fibrillation: Lack of prognostic differences between atrial fibrillation and atrial flutter (2003) (0)
Abstract 1738: Lone Atrial Fibrillation: Long-Term Clinical and Echocardiographic Follow-up from the Canadian Registry of Atrial Fibrillation (2007) (0)
Predictors of Pacemaker Dependency and Heart Failure Hospitalizations in Pacemaker Patients in the Assert Trial (2013) (0)
P.2. Syncope, Pacemaker, CRT & ICD (2005) (0)
P6351A point-of-care risk score predicts 30-day readmission in patients hospitalized with heart failure (HF): derivation and validation of the LENT index (2019) (0)
DINAMIT: Does ICD Implantation Improve Life Expectancy in Survivors of Acute Myocardial Infarction? (2000) (0)
766 Prevention of Arrhythmia Device Infection Trial (PADIT): Pilot Study Results (2012) (0)
revention of Atrial Fibrillation ith Angiotensin-Converting Enzyme nhibitors and Angiotensin Receptor Blockers (2005) (0)
176 Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers. (2016) (0)
Association of a history of falls or syncope with intracranial bleeding in patients with atrial fibrillation (2020) (0)
Azimilide reduces symptom burden at the time of arrhythmia recurrence in patients with atrial fibrillation (2002) (0)
Surgical Checklist to Reduce Pacemaker and Implantable Cardioverter-Defibrillator Lead Dislodgements (2013) (0)
Guimarães, P. O. et al. (2017) Effect of Apixaban on all-cause death in patients with atrial fibrillation: a meta-analysis based on imputed placebo (2018) (0)
Abstract 19757: Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial (2016) (0)
HIGH-VOLTAGE ICD LEAD IMPEDANCES ARE NOT INCREASED BY ROUTINE DEFIBRILLATION TESTING: Results FROM THE SIMPLE STUDY (2015) (0)
Explaining the RE-LY Trial. (2010) (0)
Atrial Fibrillation Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and (2012) (0)
Role of antithrombotic therapy in atrial fibrillation. (1994) (0)
Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants? (2012) (0)
Abstract P192: The Gap Between Guidelines and Practice for the Total Cardiovascular Care of Atrial Fibrillation Patients in an Extended Study for Re-ly Patients Receiving Dabigatran (2011) (0)
Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring (2020) (0)
Dual-chamber pacing was more effective in patients with sinus-node dysfunction. (1998) (0)
[Platelet inhibition remains the second choice. "Anticoagulation should always be the goal" (interview by Dr. med. Jochen Aumiller)]. (2009) (0)
A single-center experience in transvenous coronary sinus lead extraction and re-implantation. Technical issues and alternative re-implantation approaches (2013) (0)
Chapter 10 – Clinical Trials of Pacing Modes (2007) (0)
Abstract 18466: Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial (2012) (0)
Abstract P131: Importance of Algorithm-Consistent Warfarin Dosing in the Quality of Anticoagulation Control in Atrial Fibrillation: A Multilevel Analysis (2011) (0)
Predictors of thromboembolism in atrial fibrillation: Analysis on clinical and echocardiographic features (1996) (0)
Should Anticoagulation Be Stopped After Successful Ablation for Atrial Fibrillation (2020) (0)
P4784Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial (2019) (0)
Antecedent hypertension predisposes to arrhythmic death after acute myocardial infarction: An insight from contemporary survival studies (2003) (0)
Clinical trials in acute myocardial infarction: When should we adjust for baseline characteristics? (2000) (0)
Letter by McEvoy Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both" (2011) (0)
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy (2016) (0)
Abstract 18121: Extracranial Systemic Embolic Events in Patients With Atrial Fibrillation: Incidence and Outcomes (2013) (0)
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. Reply. (2022) (0)
1166-211 Magnesium effectively prevents postoperative atrial fibrillation in patients after heart surgery: Meta-analysis of randomized trials on 2,040 patients (2004) (0)
794 What is the Clinical Profile of “Life-Threatening” Gastrointestinal Bleeding in Anticoagulated Patients? A Sub-Analysis of the RE-LY Trial (2016) (0)
Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate (2013) (0)
114 – Prevention of Stroke in Patients With Atrial Fibrillation (2014) (0)
Abstract 329: Barriers To Hypertension Screening, Treatment And Control As Reported By Patients And Healthcare Providers (2013) (0)
Frequency and Features of Patients with Embolic Stroke of Undetermined Source(ESUS) (2014) (0)
Abstract 4095: Maintenance of Sinus Rhythm Is Not Associated with Improved Survival in Patients with Atrial Fibrillation and Heart Failure (2008) (0)
P836Benzodiazepine-free cardiac anesthesia for reduction of delirium (B-Free): a two-centre pilot study to determine the feasibility of a multi-centre, randomized, cluster crossover trial (2018) (0)
Reply to the Editor--Shocks and mortality versus pacing and mortality. (2013) (0)
Is there a gender difference in the risk of arrhythmic death after acute myocardial infarction? An insight from contemporary survival studies (2002) (0)
Abstract 10249: Association of Eligibility for a Sodium-Glucose Co-Transporter 2 Inhibitor and Cardiovascular Outcomes in Patients with Atrial Fibrillation (2021) (0)
4. Syncope Evaluation & Syncope Unit4.3 The Role of the Emergency Medical System in the Assessment and Management of Syncope (2005) (0)
Abstract WP126: Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial (2023) (0)
MP09: Canadian Community Utilization of Stroke Prevention Pilot Study-Emergency Department (C-CUSP ED) (2017) (0)
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide (2022) (0)
Resetting of a Supraventricular Tachycardia by a Ventricular Premature Beat. What is the Mechanism? (2015) (0)
Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF (2022) (0)
Abstract 23231: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
HIGH PREVALENCE OF MODIFIABLE RISK FACTORS IDENTIFIED IN PHARMACY-BASED SCREENING PROGRAM (2016) (0)
BENZODIAZEPINE-FREE CARDIAC ANESTHESIA FOR REDUCTION OF DELIRIUM (B-FREE): A TWO-CENTRE PILOT STUDY TO DETERMINE THE FEASIBILITY OF A MULTI-CENTRE, RANDOMIZED, CLUSTER CROSSOVER TRIAL (2018) (0)
Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. (2023) (0)
Upper Gastrointestinal Symptoms Related to Dabigatran. An Analysis of the RE-LY Trial with 18,113 Subjects: 94 (2011) (0)
Oral propafenone reduced symptomatic paroxysmal supraventricular arrhythmias (1991) (0)
Abstract 5795: Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm on Quality of Anticoagulation at a Specialist Anticoagulation Clinic (2009) (0)
Abstract WP177: Effects Of The Oral Factor XIa Inhibitor Asundexian On Intracranial Bleeding Among Patients With Acute Non-Cardioembolic Ischemic Stroke: PACIFIC-Stroke Randomized Trial (2023) (0)
4. Syncope Evaluation & Syncope Unit4.4 Application of the American College of Emergency Physicians (ACEP) Recommendations and a Risk Stratification System (OESIL) for Patients with Syncope Admitted in Internal Medicine Service (2005) (0)
Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations (2022) (0)
Pulmonary Vein Diameter and Post Radiofrequency Ablation Atrial Fibrillation Recurrence: Does Size Matter? (2013) (0)
Abstract 17221: Incidence of Pacemaker-Detected Atrial Tachyarrhythmias in Elderly Patients with Hypertension and a History of Stroke or Transient Ischemic Attack (2012) (0)
Vitamin K antagonists versus direct oral anticoagulants after cardiac surgery: a 31-country cohort study (2020) (0)
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". (2014) (0)
Challenges for the Basis of Practice Managing Patients with Rapid Atrial Fibrillation and Decompensated Heart Failure (2009) (0)
P3252Prospective study of tricuspid valve regurgitation associated with permanent leads in patients undergoing cardiac rhythm device implantation (2017) (0)
Abstract P7: The Impact of Cardiovascular Hospitalization on Mortality and Quality of Life Among 14,261 Atrial Fibrillation Patients in the ACTIVE Study (2011) (0)
Reply to the Editor—Electrogram Confirmation of Atrial High-Rate Episodes (2012) (0)
496: VALIDATION OF ANDEXANET ALFA REGIMEN FOR REVERSAL OF ANTICOAGULATION IN PATIENTS WITH MAJOR BLEEDING (2019) (0)
288Thrombotic events in bleeding patients treated with andexanet alpha: an ANNEXA-4 sub-study (2019) (0)
Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke (2022) (0)
360Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry (2018) (0)
Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study (2013) (0)
Left atrial dimension is associated with atrial fibrillation recurrence: four-year echo follow-up data (2002) (0)
Response to Letter Regarding Article, “Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)” (2013) (0)
Abstract 20611: Knowledge to Action: Rationale and Design of the Patient-Centred Care Transitions in Heart Failure (PACT-HF) Pragmatic Trial (2017) (0)
Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial (2021) (0)
Apixaban Reduces Stroke Risk in Patients with AF: Results from the AVERROES Trial (2010) (0)
Abstract 12618: Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran (2012) (0)
Abstract 210: Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial (2013) (0)
Letter to the Editor Narrow QRS tachycardia with long R-P (2008) (0)
ACTIVE W Substudy Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in (2011) (0)
Cardio-dynamic and vascular behaviour during head up tilt in patients with neurally mediated syncope (2005) (0)
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial (2023) (0)
Thoracoscopic Left Atrial Appendage Occlusion: We Can Do It, Now Should We? (2017) (0)
Funding: CMSisfunded bytheMedical Research Council. Conflict ofinterest: Theauthors areinvolved inastudy of theprevalence ofatrial fibrillation andofindications and contraindications fortreatment withwarfarin, whichis funded bytheStroke Association. (1995) (0)
Patients With Ventricular Premature Depolarizations (2005) (0)
Abstract 23086: Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG (2017) (0)
Prophylactic implanted defibrillator may improve survival in patients at high risk for ventricular tachyarrhythmias. (1997) (0)
Demographic parameters predict strongly all-cause and arrhythmic mortality in high risk patients after myocardial infarction in the thrombolytic era: a secondary analysis of survival trials (2002) (0)
Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial (2023) (0)
Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality. (2023) (0)
Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials (2023) (0)
Andexanet Alfa for the Management of Acute Major Bleeding Associated with FXa Inhibitors (P5.059) (2017) (0)
Letter by Longtin et al regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". (2015) (0)
A SIMPLE, POINT-OF-CARE RISK PREDICTION TOOL TO PREDICT 30-DAY OUTCOMES FOLLOWING HOSPITALIZATION FOR HEART FAILURE (2018) (0)
Abstract P6: Vitamin K Antagonist Dosing Methods and Individual Patient Quality of INR Control in the International Active W Anticoagulation Study (2011) (0)
101: PHASE 3 OF ANDEXANET ALFA FOR REVERSAL OF APIXABAN AND RIVAROXABAN ANTICOAGULATION IN OLDER SUBJECTS (2015) (0)
901 Does cardiac resynchronization therapy improve outcomes in patients with chronic atrial tachyarrhythmias? Results from the resynchronization for ambulatory heart failure trial (RAFT) (2011) (0)
Application of the American College of Emergency Physicians (ACEP) recommendations and a risk stratification score (OESIL) for patients with syncope admitted in internal medicine service (2005) (0)
Antiplatelets in patients with atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials (2021) (0)
Abstracts: Ventricular Fibrillation Induction at implant: hot issues (2009) (0)
Abstract 19004: The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis (2016) (0)
Prophylactic amiodarone in older patients receiving β -blockers and undergoing open-heart surgery was efficacious (2001) (0)
Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS (2014) (0)
Omega-3 fatty acids and sudden arrhythmic death. (2006) (0)
A hybrid automated event adjudication system for clinical trials (2023) (0)
Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study (2014) (0)
3. Vasovagal Syncope, Tilt Testing (2005) (0)
Risk of ischemic stroke or systemic embolism in aspirin-treated patients according to clinical presentation of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE or AVERROES (2014) (0)
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors (2023) (0)
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. Reply. (2021) (0)
Trial Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Quality of Anticoagulation Control Between Centers and Countries : An Analysis of Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the (2012) (0)
Long-Term Dabigatran Extension Study for Stroke Prevention in Treatment for Atrial Fibrillation (2012) (0)
ABC-AF STROKE AND BLEEDING SCORES ARE USEFUL TOOLS TO ESTIMATE THE BALANCE BETWEEN BENEFITS AND RISKS WITH DIFFERENT ANTITHROMBOTIC TREATMENTS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE AND RE-LY TRIALS (2022) (0)
Is atrial fibrillation pattern a risk factor for thromboembolism in nonrheumatic atrial fibrillation (1996) (0)
The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. (2022) (0)
Late-Breaking Clinical Trials Session II: New Data for Device Therapies (2019) (0)
4940Predicting risk at the point of care: NT-proBNP improves performance of the LACE index among patients hospitalized for Heart Failure (HF) (2018) (0)
DEPRESSION IS ASSOCIATED WITH HIGHER MORTALITY IN PATIENTS WITH A HISTORY OF VENTRICULAR FIBRILLATION/TACHYCARDIA (1999) (0)
P2859Low rates of mechanical failures of silicone-polyurethane copolymer-coated ICD leads: 11 years prospective follow-up (2019) (0)
Differences in baseline electrophysiologic properties and electrical remodeling among pacemaker patients who develop atrial tachyarrhythmias : results of the ASSERT mechanisms of atrial fibrillation St (2011) (0)
THE SIMPLE TRIAL: A LARGE ICD IMPLANT COHORT SHOWING A LOW RATE OF INFECTION (2016) (0)
Abstract 3776: Apixaban Compared To Aspirin In Patients With Atrial Fibrillation And Prior Transient Ischemic Attack Or Stroke: Results Of A Predefined Subgroup Analysis From Averroes (2012) (0)
Abstract 3700: Impact of Vascular Events on Mortality in AF Patients: Insights from ACTIVE W (2006) (0)
Response to the Letter by Spurling and Colleagues (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stuart James Connolly?

Stuart James Connolly is affiliated with the following schools:

Stuart James Connolly's Academic­Influence.com Rankings

Why Is Stuart James Connolly Influential?

Stuart James Connolly's Published Works

Published Works

What Schools Are Affiliated With Stuart James Connolly?

Stuart James Connolly's AcademicInfluence.com Rankings